Cover Image
市場調查報告書

全球泌尿系統癌症治療藥市場預測

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics

出版商 GBI Research 商品編碼 363981
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
全球泌尿系統癌症治療藥市場預測 Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics
出版日期: 2016年06月16日 內容資訊: 英文 143 Pages
簡介

全球泌尿系統癌症治療藥市場的收益2015年為179億美元,預計2022年擴大到359億美元。市場預計2015年∼2022年以10.39%的年複合成長率成長。

本報告提供全球泌尿系統癌症治療藥市場相關調查分析,主要上市產品,開發平台情形的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 主要上市產品

  • 概要
  • Zytiga (abiraterone acetate)
  • Xtandi (enzalutamide)
  • Sutent (sunitinib malate)
  • Votrient (pazopanib hydrochloride)
  • Inlyta (axitinib)
  • Jevtana (cabazitaxel)
  • Xofigo (radium Ra 223 dichloride)
  • Provenge (sipuleucel-T)
  • Opdivo (nivolumab)
  • 結論

第4章 開發平台情形的評估

  • 概要
  • 開發平台開發情形
  • 開發平台的分子標靶
  • 臨床實驗
  • 結論
  • 主要的開發中產品的評估
  • 結論

第5章 複數方案的市場預測

  • 綜合性的市場規模
  • 學名藥的普及
  • 收益預測:各分子標靶

第6章 企業分析與地位

  • 收益與市場佔有率分析:各企業
  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC412MR

Executive Summary

Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer - the key indications covered in this report - accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.

A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies - such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

  • Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
  • How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
  • What proportion of the key players' revenues will be attributable to urological cancers?

Reasons to buy

  • This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types
  • Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers
  • Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Cluster Introduction
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Etiology
    • 2.3.2. Pathophysiology
  • 2.4. Co-morbidities and Complications
  • 2.5. Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
    • 2.5.1. Bladder Cancer
    • 2.5.2. Kidney Cancer
    • 2.5.3. Prostate Cancer
    • 2.5.4. Testicular Cancer
  • 2.6. Treatment
    • 2.6.1. Chemotherapy
    • 2.6.2. Surgery and Radiation Therapy
    • 2.6.3. Hormonal Therapies
    • 2.6.4. Targeted Therapies

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Zytiga (abiraterone acetate)
  • 3.3. Xtandi (enzalutamide)
  • 3.4. Sutent (sunitinib malate)
  • 3.5. Votrient (pazopanib hydrochloride)
  • 3.6. Inlyta (axitinib)
  • 3.7. Jevtana (cabazitaxel)
  • 3.8. Xofigo (radium Ra 223 dichloride)
  • 3.9. Provenge (sipuleucel-T)
  • 3.10. Opdivo (nivolumab) - Bristol-Myers Squibb
  • 3.11. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
  • 4.5. Conclusion
  • 4.6. Assessment of Key Pipeline Products
    • 4.6.1. Atezolizumab - Roche
    • 4.6.2. Durvalumab - AstraZeneca
    • 4.6.3. Durvalumab + Tremelimumab - MedImmune
    • 4.6.4. Apalutamide - Johnson & Johnson
    • 4.6.5. Avelumab - Merck KGaA
    • 4.6.6. Tivozanib - EUSA Pharma
    • 4.6.7. Eoquin - Spectrum Pharmaceuticals
    • 4.6.8. Prostvac - Bavarian Nordic
  • 4.7. Conclusion

5. Multi-Scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Androgen Receptor Antagonists
    • 5.3.2. Programmed Cell Death Protein 1 Inhibitor
    • 5.3.3. VEGF Inhibitors
    • 5.3.4. GnRH Inhibitors
    • 5.3.5. Tubulin Inhibitors
    • 5.3.6. CTLA-4 Inhibitors

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Pfizer - Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta?
    • 6.1.2. Novartis - How Will Upcoming Patent Expiries Affect Urological Cancer Revenues?
    • 6.1.3. Johnson & Johnson - How Will Zytiga Perform in an Increasingly Competitive Prostate Cancer Treatment Market?
    • 6.1.4. Astellas - What Will Become of Xtandi?
    • 6.1.5. AstraZeneca - Will Sales Revenues Increase over the Forecast Period?
    • 6.1.6. Bristol-Myers Squibb - How Will Cancer Immunotherapies Affect Urological Cancers?
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Molecular Target and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Molecular Target and Value

8. Appendix

  • 8.1. References
  • 8.2. Table of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Urologic Oncology, Global, Symptoms of the Most Prevalent Urological Cancers, 2016
  • Table 2: Urologic Oncology, Global, Complications Associated with Bladder, Kidney, Prostate and Testicular Cancers
  • Table 3: Urologic Oncology, Global, Epidemiology of The Most Prevalent Urological Cancers, 2015
  • Table 4: Urologic Oncology, Optimal and Actual Chemotherapy Usage Rates Across All Cancer Stages, 2010
  • Table 5: Urologic Oncology, Global, Reconstructive Surgery following Bladder Cancer Resection, 2016
  • Table 6: Urologic Oncology, Optimal and Actual Radiation Therapy Usage Rates in US, 1995-2000
  • Table 7: Urologic Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2016
  • Table 8: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2016
  • Table 9: Urologic Oncology Therapeutics Market, Global, Approved Indications for Sutent, 2016
  • Table 10: Urologic Oncology Therapeutics Market, Global, Approved Indications for Votrient, 2016
  • Table 11: Urologic Oncology Therapeutics Market, Global, Approved Indications for Inlyta, 2016
  • Table 12: Urologic Oncology Therapeutics Market, Global, Approved Indications for Jevtana, 2016
  • Table 13: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xofigo, 2016
  • Table 14: Urologic Oncology Therapeutics Market, Global, Approved Indications for Provenge, 2016
  • Table 15: Urologic Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2016
  • Table 16: Urologic Oncology, Global, Usage of Generics Across Key Indications, 2016
  • Table 17: Urologic Oncology, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Table 18: Urologic Oncology, Global, Co-development Deals Valued Above $100m, 2006-2016
  • Table 19: Oncology, Global, All Clinical Trial Stage Pipeline Products, 2016
  • Table 20: Abbreviations

List of Figures

  • Figure 1: Urologic Oncology, Major Markets, Treatment Usage Patterns for Bladder Cancer, Patients ('000), 2015-2022
  • Figure 2: Urologic Oncology, Major Markets, Treatment Usage Patterns for Kidney Cancer, Patients ('000), 2015-2022
  • Figure 3: Urologic Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients ('000), 2015-2022
  • Figure 4: Urologic Oncology, Major Markets, Treatment Usage Patterns for Testicular Cancer, Patients ('000), 2015-2022
  • Figure 5: Urological Cancer, Global, Key Marketed Products and Approved Indications, 2015
  • Figure 6: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Zytiga ($bn), 2011-2022
  • Figure 7: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xtandi ($bn), 2012-2022
  • Figure 8: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Sutent ($bn), 2006-2022
  • Figure 9: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Votrient ($bn), 2010-2022
  • Figure 10: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Inlyta ($m), 2012-2022
  • Figure 11: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Jevtana ($m), 2012-2022
  • Figure 12: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xofigo ($bn), 2013-2022
  • Figure 13: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Provenge ($m), 2010-2022
  • Figure 14: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Opdivo ($bn), 2015-2022
  • Figure 15: Urologic Oncology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 16: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 17: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016
  • Figure 18: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016
  • Figure 19: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Molecular Target, 2016
  • Figure 20: Urologic Oncology Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • Figure 21: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016
  • Figure 22: Urologic Oncology Therapeutics Market, Global, Urologic Clinical Trial by Indication (%), 2006-2016
  • Figure 23: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 24: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 25: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 26: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 27: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (months), 2006-2016
  • Figure 28: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 29: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 30: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 31: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
  • Figure 32: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 33: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 34: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 35: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
  • Figure 36: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 37: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 38: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 39: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for atezolizumab ($bn), 2016-2022
  • Figure 40: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab ($bn), 2017-2022
  • Figure 41: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab + Tremelimumab ($m), 2018-2022
  • Figure 42: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Apalutamide ($m), 2018-2022
  • Figure 43: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Avelumab ($m), 2016-2022
  • Figure 44: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Tivozanib ($m), 2016-2022
  • Figure 45: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Eoquin ($m), 2017-2022
  • Figure 46: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Prostvac ($m), 2016-2022
  • Figure 47: Urologic Oncology, Global, Market Size ($bn), 2015-2022
  • Figure 48: Urologic Oncology, Global, Market Size ($bn), 2015-2022
  • Figure 49: Urologic Oncology, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
  • Figure 50: Urologic Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2015-2022
  • Figure 51: Urologic Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1 Inhibitor ($bn), 2015-2022
  • Figure 52: Urologic Oncology, Global, Annual Revenue Forecast for VEGF Inhibitors ($bn), 2015-2022
  • Figure 53: Urologic Oncology, Global, Annual Revenue Forecast for GNRH Inhibitors ($m), 2015-2022
  • Figure 54: Urologic Oncology, Global, Annual Revenue Forecast for Tubulin Inhibitors ($m), 2015-2022
  • Figure 55: Urologic Oncology, Global, Annual Revenue Forecast for CTLA-4 ($m), 2017-2022
  • Figure 56: Urologic Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2015-2022
  • Figure 57: Urologic Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022
  • Figure 58: Urologic Oncology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 59: Urologic Oncology, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
  • Figure 60: Urologic Oncology, Global, Revenues by Product Type, 2015-2022
  • Figure 61: Urologic Oncology, Global, Pfizer Urologic Oncology Annual Revenue Forecast ($bn), 2015-2022
  • Figure 62: Urologic Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2015-2022
  • Figure 63: Urologic Oncology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
  • Figure 64: Urologic Oncology, Global, Astellas Pharma Inc. Annual Revenue Forecast ($bn), 2015-2022
  • Figure 65: Urologic Oncology, AstraZeneca Plc. Annual Revenue Forecast ($bn), 2015-2022
  • Figure 66: Urologic Oncology, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2015-2022
  • Figure 67: Urologic Oncology, Global, Companies by Type, 2015-2022
  • Figure 68: Urologic Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Urological Cancer Specialization, 2015-2022
  • Figure 69: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancer, 2015-2022
  • Figure 70: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancers, Top Six Companies ($bn), 2015-2022
  • Figure 71: Urologic Oncology, Global, Licensing Deals, 2006-2016
  • Figure 72: Urologic Oncology, Global, Licensing Deals by Indication and Value, 2006-2016
  • Figure 73: Urologic Oncology, Global, Licensing Deals, 2006-2016
  • Figure 74: Urologic Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2016
  • Figure 75: Urologic Oncology, Global, Co-development Deals, 2006-2016
  • Figure 76: Urologic Oncology, Global, Co-development Deals by Indication and Value, 2006-2016
  • Figure 77: Urologic Oncology, Global, Co-development Deals, 2006-2016
  • Figure 78: Urologic Oncology, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2016
Back to Top